Hypotyreóza u pacientů se srdečním onemocněním
[Hypothyroidism in patients with heart disease]
Jazyk čeština Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
29120652
PII: 62120
- MeSH
- hormonální substituční terapie MeSH
- hypotyreóza komplikace farmakoterapie MeSH
- klinické rozhodování MeSH
- lidé MeSH
- nemoci srdce komplikace MeSH
- rizikové faktory MeSH
- thyroxin terapeutické užití MeSH
- věkové faktory MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- thyroxin MeSH
Hypothyroidism is frequently found in patients with heart disease. It is a risk factor for atherosclerosis and ischemic heart disease and has a direct negative effect on both the left and right ventricular functions (hypothyroidism-induced cardiomyopathy). The confirmed manifest hypothyroidism is always a reason for replacement therapy with levothyroxine; regarding patients with heart disease, we always begin treatment with a small dose and increase it gradually. The treatment of subclinical hypothyroidism in patients with heart disease is disputable and its benefits probably depend on age. At a higher age, the therapy-related risks often outweigh its benefits, so we make do with the target levels of the thyroid stimulating hormone being within the upper band of the normal range, or even slightly above it, rather than overdosing the patient. To summarize in a simplified way, the treatment of subclinical hypothyroidism in patients with heart disease is the most effective in younger individuals, mainly those aged below 65, while at a higher age > 80 years the risk usually outweighs the benefit.Key words: cardiovascular risk - hypothyroidism - ischemic heart disease - left ventricular dysfunction - right ventricular dysfunction - subclinical hypothyroidism - thyroid peroxidase antibodies.